Type: Public
On the web: http://www.auxilium.com
Employees: 530
Employee growth: (6.2%)

Auxilium Pharmaceuticals wants to be firm on some things and flexible on others. The biopharmaceutical developer markets products that include Testim, a topical testosterone gel used to treat hypogonadism (low testosterone production) and XIAFLEX, an injectable enzyme approved to treat Dupuytren's contracture (a progressive disease which causes a person's fingers to permanently contract). While third parties manufacture its finished products, Auxilium manufactures the active ingredient for XIAFLEX at its own facility. The company's pipeline of candidates includes potential treatments for unusual soft tissue conditions and pain.

Key numbers for fiscal year ending December, 2011:
Sales: $264.3M
One year growth: 25.0%
Net income: ($32.9)M

Officers:
Chairman: Rolf A. Classon
President, CEO, and Director: Armando Anido
CFO: James E. (Jim) Fickenscher

Competitors:
Abbott Labs
Par Pharmaceutical Companies
Watson Pharmaceuticals